StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Prevymis (letermovir by Quarter

Prevymis (letermovir — CMV prophylaxis) — U.S. sales ($M) ($M)

QuarterlyAnnual

Merck Prevymis (letermovir: $147M in Q2 2026, up 27.8% from a year earlier. That is the highest of the 30 quarters on record here.

Latest, Q2 2026
147
Period ended Jun 30, 2026
Change on a year earlier
+27.8%
115 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Prevymis | 295 | 228 | 29 | 147 | 115 | 28 | 148 | 113 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPrevymis (letermovir — CMV prophylaxis) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026147+27.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026135+32.4%Form 10-Q (filed 2026-05-04) ↗
Q4 2025Dec 31, 2025130+22.6%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 2025128+26.7%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 2025115+27.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025102+37.8%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 2024106+35.9%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024101+44.3%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202490+47.5%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202474+37.0%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202378+50.0%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202370+42.9%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202361+29.8%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202354+35.0%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202252+23.8%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202249+25.6%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up prevymis (letermovir

Cite this data

StockData. (2026). Merck Prevymis (letermovir ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-prevymis-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.